U.S. FDA Approval Summary: Nivolumab for Treatment of Unresectable or Metastatic Melanoma Following Progression on Ipilimumab by Hazarika, Maitreyee, Chuk, Meredith K, Theoret, Marc R, Mushti, Sirisha, He, Kun, Weis, Shawna L, Putman, Alexander H, Helms, Whitney S, Cao, Xianhua, Li, Hongshan, Zhao, Hong, Zhao, Liang, Welch, Joel, Graham, Laurie, Libeg, Meredith, Sridhara, Rajeshwari, Keegan, Patricia, Pazdur, Richard

Get full text

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma by Barone, Amy, Hazarika, Maitreyee, Theoret, Marc R, Mishra-Kalyani, Pallavi, Chen, Huanyu, He, Kun, Sridhara, Rajeshwari, Subramaniam, Sriram, Pfuma, Elimika, Wang, Yaning, Li, Hongshan, Zhao, Hong, Zirkelbach, Jeanne Fourie, Keegan, Patricia, Pazdur, Richard

Get full text

Tasigna for Chronic and Accelerated Phase Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia Resistant to or Intolerant of Imatinib by HAZARIKA, Maitreyee, XIAOPING JIANG, TIMMER, William, HARAPANHALLI, Ravi, DAGHER, Ramzi, JUSTICE, Robert, PAZDUR, Richard, QI LIU, LEE, Shwu-Luan, RAMCHANDANI, Roshni, GARNETT, Christine, ORR, Micheal S, SRIDHARA, Rajeshwari, BOOTH, Brian, LEIGHTON, John K

Get full text

FDA Drug Approval Summaries: Pemetrexed (Alimta®) by Hazarika, Maitreyee, White, Robert M., Johnson, John R., Pazdur, Richard

Get full text

Pemetrexed in Malignant Pleural Mesothelioma by HAZARIKA, Maitreyee, WHITE, Robert M, MORSE, David E, LOSTRITTO, Richard, GARVEY, Patricia, JOHNSON, John R, PAZDUR, Richard, BOOTH, Brian P, WANG, Yong-Cheng, LEE HAM, Doo Y, CHENG YI LIANG, RAHMAN, Atiqur, GOBBURU, Jogarao V. S, NING LI, SRIDHARA, Rajeshwari

Get full text

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis by Beaver, Julia A, Hazarika, Maitreyee, Mulkey, Flora, Mushti, Sirisha, Chen, Huanyu, He, Kun, Sridhara, Rajeshwari, Goldberg, Kirsten B, Chuk, Meredith K, Chi, Dow-Chung, Chang, Jennie, Barone, Amy, Balasubramaniam, Sanjeeve, Blumenthal, Gideon M, Keegan, Patricia, Pazdur, Richard, Theoret, Marc R

Get full text

FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation by Kim, Geoffrey, McKee, Amy E, Ning, Yang-Min, Hazarika, Maitreyee, Theoret, Marc, Johnson, John R, Xu, Qiang Casey, Tang, Shenghui, Sridhara, Rajeshwari, Jiang, Xiaoping, He, Kun, Roscoe, Donna, McGuinn, W David, Helms, Whitney S, Russell, Anne Marie, Miksinski, Sarah Pope, Zirkelbach, Jeanne Fourie, Earp, Justin, Liu, Qi, Ibrahim, Amna, Justice, Robert, Pazdur, Richard

Get full text

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression by Beaver, Julia A., Hazarika, Maitreyee, Mulkey, Flora, Mushti, Sirisha, Chen, Huanyu, He, Kun, Sridhara, Rajeshwari, Goldberg, Kirsten B., Chuk, Meredith K., Chi, Dow-Chung, Chang, Jennie, Barone, Amy, Balasubramaniam, Sanjeeve, Blumenthal, Gideon M., Keegan, Patricia, Pazdur, Richard, Theoret, Marc R.

Get full text

Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy by Hazarika, Maitreyee, Rock, Edwin, Williams, Gene, Dagher, Ramzi, Sridhara, Rajeshwari, Booth, Brian, Farrell, Ann, Justice, Robert, Pazdur, Richard

Get full text